UBS AM’s AbbVie ABBV Stock Holding History

UBS AM’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.08B	Buy	14,161,606 +1,237,295	+10%	+$274M	0.64%	23
2025 Q4	$2.95B	Buy	12,924,311 +343,190	+3%	+$78.2M	0.62%	18
2025 Q3	$2.91B	Sell	12,581,121 -2,021,476	-14%	-$412M	0.63%	22
2025 Q2	$2.71B	Buy	14,602,597 +1,830,743	+14%	+$340M	0.55%	26
2025 Q1	$2.68B	Buy	12,771,854 +713,148	+6%	+$139M	0.69%	20
2024 Q4	$2.14B	Buy	12,058,706 +1,882,780	+19%	+$346M	0.5%	30
2024 Q3	$2.01B	Buy	10,175,926 +582,953	+6%	+$109M	0.52%	27
2024 Q2	$1.65B	Buy	9,592,973 +838,012	+10%	+$139M	0.47%	31
2024 Q1	$1.59B	Sell	8,754,961 -89,025	-1%	-$15.3M	0.57%	26
2023 Q4	$1.37B	Sell	8,843,986 -562,261	-6%	-$82M	0.54%	28
2023 Q3	$1.4B	Sell	9,406,247 -577,122	-6%	-$84.7M	0.63%	21
2023 Q2	$1.59B	Hold	9,983,369	–	–	0.77%	15
2023 Q1	$1.59B	Sell	9,983,369 -786,314	-7%	-$120M	0.77%	15
2022 Q4	$1.74B	Sell	10,769,683 -60,995	-0.6%	-$9.35M	0.91%	10
2022 Q3	$1.45B	Sell	10,830,678 -180,708	-2%	-$25.9M	0.82%	11
2022 Q2	$1.69B	Buy	11,011,386 +938,091	+9%	+$143M	0.88%	11
2022 Q1	$1.63B	Sell	10,073,295 -1,064,271	-10%	-$155M	0.7%	16
2021 Q4	$1.51B	Sell	11,137,566 -1,096,380	-9%	-$130M	0.58%	21
2021 Q3	$1.32B	Buy	12,233,946 +1,166,720	+11%	+$133M	0.55%	26
2021 Q2	$1.25B	Sell	11,067,226 -429,138	-4%	-$48.3M	0.53%	25
2021 Q1	$1.24B	Buy	11,496,364 +57,833	+0.5%	+$6.19M	0.55%	25
2020 Q4	$1.23B	Buy	11,438,531 +2,263,374	+25%	+$218M	0.57%	23
2020 Q3	$804M	Buy	9,175,157 +426,045	+5%	+$40.1M	0.43%	41
2020 Q2	$859M	Buy	8,749,112 +2,666,133	+44%	+$235M	0.52%	29
2020 Q1	$463M	Buy	6,082,979 +290,574	+5%	+$24.8M	0.33%	63
2019 Q4	$513M	Sell	5,792,405 -72,771	-1%	-$6.04M	0.31%	62
2019 Q3	$444M	Buy	5,865,176 +141,629	+2%	+$9.71M	0.3%	65
2019 Q2	$416M	Sell	5,723,547 -4,103	-0.1%	-$322K	0.3%	65
2019 Q1	$462M	Buy	5,727,650 +167,401	+3%	+$13.7M	0.34%	56
2018 Q4	$513M	Sell	5,560,249 -35,240	-0.6%	-$3.1M	0.44%	41
2018 Q3	$529M	Sell	5,595,489 -43,583	-0.8%	-$4.13M	0.39%	47
2018 Q2	$522M	Sell	5,639,072 -277,013	-5%	-$27.1M	0.4%	40
2018 Q1	$560M	Buy	5,916,085 +200,298	+4%	+$22M	0.44%	36
2017 Q4	$553M	Sell	5,715,787 -211,917	-4%	-$20M	0.47%	38
2017 Q3	$527M	Sell	5,927,704 -469,164	-7%	-$35.7M	0.48%	41
2017 Q2	$464M	Buy	6,396,868 +387,657	+6%	+$26.1M	0.45%	44
2017 Q1	$392M	Buy	6,009,211 +588,910	+11%	+$37M	0.4%	48
2016 Q4	$339M	Buy	5,420,301 +296,622	+6%	+$18.1M	0.38%	49
2016 Q3	$323M	Buy	5,123,679 +265,713	+5%	+$17.2M	0.35%	60
2016 Q2	$301M	Sell	4,857,966 -40,398	-0.8%	-$2.46M	0.34%	64
2016 Q1	$280M	Sell	4,898,364 -1,520,644	-24%	-$84.8M	0.32%	67
2015 Q4	$380M	Sell	6,419,008 -644,181	-9%	-$37.1M	0.43%	46
2015 Q3	$384M	Sell	7,063,189 -811,601	-10%	-$52.8M	0.42%	45
2015 Q2	$529M	Sell	7,874,790 -1,755,164	-18%	-$115M	0.51%	37
2015 Q1	$564M	Sell	9,629,954 -2,817,025	-23%	-$170M	0.54%	35
2014 Q4	$815M	Buy	12,446,979 +1,775,058	+17%	+$112M	0.78%	17
2014 Q3	$616M	Buy	10,671,921 +896,538	+9%	+$49.8M	0.61%	30
2014 Q2	$552M	Buy	9,775,383 +878,153	+10%	+$46.1M	0.56%	34
2014 Q1	$457M	Buy	8,897,230 +1,268,650	+17%	+$64.1M	0.49%	41
2013 Q4	$403M	Buy	7,628,580 +93,005	+1%	+$4.57M	0.46%	45
2013 Q3	$337M	Buy	7,535,575 +261,097	+4%	+$11.6M	0.42%	49
2013 Q2	$301M	Buy	+7,274,478	New	+$318M	0.39%	55

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM's ABBV Position: Q1 2026 in Review

UBS AM increased its AbbVie (ABBV) stake by 9.6% in Q1 2026, buying an estimated $274M and bringing the position to 14,161,606 shares worth $3.08B. The position accounts for 0.64% of the portfolio, ranked #23.

UBS AM first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

UBS AM held 14,161,606 shares of AbbVie worth $3.08B as of Q1 2026.
UBS AM bought 1,237,295 AbbVie shares in Q1 2026, an estimated $274M.
AbbVie made up 0.64% of UBS AM's portfolio in Q1 2026, its #23 holding.
UBS AM first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.